BioCryst Pharmaceuticals, Inc.
BCRX
$8.80
$0.222.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.48% | 209.09% | 36.14% | 49.41% | 56.89% |
| Total Other Revenue | -- | -- | -- | -- | 189.96% |
| Total Revenue | 7.48% | 209.09% | 36.14% | 49.41% | 56.89% |
| Cost of Revenue | 57.02% | -11.02% | 5.64% | 17.45% | -12.40% |
| Gross Profit | -12.52% | 364.00% | 54.69% | 67.36% | 130.42% |
| SG&A Expenses | 14.65% | 13.75% | 27.52% | 42.67% | 38.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.91% | 3.77% | 18.66% | 32.81% | 15.91% |
| Operating Income | -118.08% | 8,321.30% | 284.70% | 239.98% | 246.51% |
| Income Before Tax | -95,193.40% | 1,054.24% | 190.21% | 151.88% | 102.16% |
| Income Tax Expenses | 38.29% | 170.15% | -231.23% | 714.53% | 98.90% |
| Earnings from Continuing Operations | -2,255,762.50% | 1,017.50% | 191.92% | 140.12% | 100.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,255,762.50% | 1,017.50% | 191.92% | 140.12% | 100.09% |
| EBIT | -118.08% | 8,321.30% | 284.70% | 239.98% | 246.51% |
| EBITDA | -112.88% | 11,033.92% | 240.10% | 231.63% | 252.01% |
| EPS Basic | -1,489,850.00% | 1,001.93% | 190.56% | 139.58% | 100.12% |
| Normalized Basic EPS | -2,686.96% | 1,138.66% | 208.87% | 183.91% | 102.17% |
| EPS Diluted | -2,980,100.00% | 967.28% | 185.71% | 132.57% | 100.06% |
| Normalized Diluted EPS | -2,804.55% | 1,099.33% | 204.19% | 179.95% | 102.07% |
| Average Basic Shares Outstanding | 15.98% | 1.73% | 1.58% | 1.50% | 1.37% |
| Average Diluted Shares Outstanding | 12.54% | 5.73% | 6.27% | 6.52% | 4.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |